Highlights newsletter 3

This newsletter presents you the following key sessions:

1. Video-interview with Karel Fostier, MD, about proteasome inhibitors as therapeutic option for patients with
    multiple myeloma

2. Retrospective observational trial evaluating the efficacy and safety of high-dose bendamustine plus brentuximab
    vedotin in patients with refractory / relapsed Hodgkin lymphoma

3. Preclinical data on the optimization of hematopoietic stem cell transplantations

4. Pivotal ZUMA-1 study: axicabtagene ciloleucel (axi-cel) improves outcome for patients with refractory aggressive
    non-Hodgkin lymphoma

5. Eltrombopag use in adult ITP patients from the UK Adult ITP Registry